Could a smartphone app replace hospital visits for Women's emergency aftercare?
NCT ID NCT06615843
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether using a health app for follow-up after a gynecological emergency is as good as or better than traditional in-person visits. About 200 women aged 18-60 with conditions like ectopic pregnancy or miscarriage will either use the app to log symptoms and get care instructions or attend standard clinic appointments. The goal is to see if the app improves patient satisfaction and reduces hospital time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- connected health app
- What this could lead to
- If successful, this could offer a more convenient and satisfying way to manage recovery from gynecological emergencies at home, reducing the need for hospital visits.
- What could go wrong
- This is a small, early-stage study (200 participants) comparing app-based care to standard in-person follow-up. The app may not work for everyone, especially those uncomfortable with technology, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women aged 18 and 60 years * No consultation at the gynecological emergency department in the previous month and/or for the same pregnancy. * Requires post-emergency follow-up for one of the following clinical conditions: * Genital Infections (IGH): Acute pelvic pain with or without leucorrhea requiring antibiotic treatment * Ectopic Pregnancy (GEU): Non-complicated, not ruptured, no significant effusion on ultrasound, GEU \&lt; 4 cm, no cardiac activity if embryo present, stable hemodynamic state, HCG \&lt; 5000, compliant patient, no contraindications for Methotrexate * Early Pregnancy of Uncertain Viability (GLI): Early stage with a positive bHCG test, no visible gestational sac on ultrasound, no effusion, bHCG \&lt; 1500 IU * Missed Miscarriage (GAM): Confirmed by an intrauterine gestational sac ≥ 25mm without an embryo or an intrauterine gestational sac with an embryo ≥ 7mm without visible cardiac activity, treated with Misoprostol * First Trimester Bleeding (MTRt1): Moderate vaginal bleeding with an ongoing intrauterine pregnancy without hemodynamic instability * Hyperemesis Gravidarum (VG): Severe vomiting before 12 weeks of pregnancy without severe criteria necessitating emergency follow-up Exclusion Criteria: * Severe clinical intolerance, defined by: * Signs of severe sepsis with unstable hemodynamics (TA with SBP \< 90 mmHg and FC ≥ 105 bpm) * Abdominal defense or contracture * Pain not controlled by level 1 analgesics (EVA \<7) * Severe dehydration defined by a body weight loss of more than 10% * Total food intolerance due to vomiting necessitating hospitalization * Uncontrolled active hemorrhage * Significant ultrasound findings: * Tubo-ovarian abscess ≥ 3 cm * Significant intra-abdominal effusion * Non-French speaking patients * Inability to download or use the digital application due to precarious or isolated digital circumstances * Refusal to sign consent form * Patients under legal guardianship or court protection (tutelage, curatorship, or guardianship) * Patients not affiliated with a social security system
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Abortion, missed are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpital Cochin
RECRUITINGParis, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can big data improve safety in gynecologic surgery?
- Can a new score catch severe pregnancy sickness that others miss?
- Tiny hairs in fallopian tubes may hold key to ectopic pregnancy
- Could a simple wristband replace drugs for severe morning sickness?
- Could a breast cancer drug treat ectopic pregnancy?
- Fast new swab test could speed up vaginitis diagnosis